New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 13, 2013
13:17 EDTSNY, GS, VPHM, SHPGViroPharma hires Goldman to explore sale, Bloomberg says
ViroPharma (VPHM) has hired Goldman Sachs (GS) to explore a sale after receiving takeover interest from Sanofi (SNY) and Shire (SHPG), reports Bloomberg, citing people with knowledge of the process. Shares of ViroPharma traded sharply higher following initial headlines of the report, and are currently up better than 25% in afternoon trade. U.S.-listed shares of Shire are off their worst levels and have turned positive following the report, while Sanofi shares are little changed. Reference Link
News For VPHM;SNY;SHPG;GS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 15, 2015
11:56 EDTSNYSanofi initiated with a Buy at Societe Generale
Subscribe for More Information
07:41 EDTSNYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
06:11 EDTGSRegulators seek to end 'too big to fail' firms, WSJ reports
Subscribe for More Information
April 14, 2015
14:05 EDTGSGoldman Sachs April volatility elevated into Q1 and outlook
Subscribe for More Information
April 13, 2015
08:42 EDTGSPandora rises after Spotify reportedly valued above $8B in fundraising
Subscribe for More Information
07:20 EDTSHPGShire price target raised to $288 from $267 at JPMorgan
JPMorgan raised its price target for Shire to $288 after lifting its estimates for Lifitegrast in dry eye following the FDA's Priority Review designation. The firm believes the FDA is very likely to approve the application in October of this year, without waiting for the third Phase III study late 2015. It upped its 2020 Lifitegrast forecasts by $600M to $900M and reiterates an Overweight rating on Shire.
06:39 EDTGSGoldman Sachs in talks to sell NPL business of Archon to D.E. Shaw, Reuters says
Subscribe for More Information
April 10, 2015
17:26 EDTGSSpotify close to deal to raise $400M, WSJ reports
Subscribe for More Information
April 9, 2015
13:27 EDTSHPGShire announces FDA Priority Review designation for lifitegrast
Subscribe for More Information
10:48 EDTSHPGDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
07:17 EDTGSGoldman Sachs April volatility elevated into Q1 and outlook
Goldman Sachs April call option implied volatility is at 24, May is at 19, July is at 18; compared to its 26-week average of 20 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 16.
05:27 EDTSHPGShire reports results from three placebo-controlled Phase 2 studies of SHP625
Subscribe for More Information
April 8, 2015
12:36 EDTGSGoogle, Facebook not discussing Twitter buyout, Re/code reports
Subscribe for More Information
10:26 EDTGSBofA Merill Lynch names De Giorgi, Assef as investment banking co-heads, FT says
Subscribe for More Information
April 7, 2015
10:10 EDTSHPGJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
08:11 EDTGSGoldman Sachs, Morgan Stanley estimates raised at Susquehanna
Susquehanna raised its estimates for both Goldman Sachs (GS) and Morgan Stanley (MS) to reflect a strong quarter for FICC driven by interest rate and currency volatility and more stable credit markets as well as better I&L. Susquehanna maintains Neutral ratings on both Goldman Sachs and Morgan Stanley shares.
08:10 EDTSHPGShire shares pricing in worst case scenario for patents, says Citigroup
Subscribe for More Information
07:14 EDTSNYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:13 EDTSHPGShire patent challenges only modest threat, says Jefferies
Subscribe for More Information
05:23 EDTSHPGShire reaches agreement with FDA on clear regulatory path for SHP465
Shire announces that it has reached an agreement with the FDA on a clear regulatory path for SHP465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder, or ADHD, in adults. Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD. While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The company anticipates the clinical trial's first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then expects to submit to the FDA by 2Q17 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire's announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use